Neuroendocrine effects of perfluorooctane sulfonate in rats. by Austin, Maureen E et al.
During the last three decades, there has been
a steady increase in the use of perﬂuorinated
compounds as components of adhesives, cos-
metics, paper coatings, fire retardants, sur-
factants, lubricants, and insecticides. These
compounds are used extensively in the
apparel, leather, and upholstery industries. As
surface treatment agents, they provide soil,
oil, and water resistance to personal apparel
and leather, fabric, upholstery, and carpets
(Kannan et al. 2002; Seacat et al. 2002;
Starkov and Wallace 2002). Perfluorinated
chemicals are also produced for paper protec-
tion, including food contact applications
(plates, food containers, bags, and wraps) and
non-food-contact applications (folding car-
tons, carbonless forms, and masking papers;
Kannan et al. 2002; Seacat et al. 2002).
Release of perﬂuorinated compounds into the
environment can occur from product manu-
facturing processes, supply chains, product
use, and disposal. Perfluorooctane sulfonate
(PFOS) is a primary degradative product
of several sulfonyl-based organofluorine
compounds (Figure 1).
PFOS and related ﬂuorochemicals are per-
sistent and bioaccumulative pollutants (Giesy
and Kannan 2001; Kannan et al. 2001a,
2001b). PFOS has been detected in the liver
and blood plasma of wildlife on a global scale
(Giesy and Kannan 2001). Exposure to PFOS
affects the liver primarily and causes vacuola-
tion and hypertrophy of hepatic cells (Borges
et al. 1978; Butenhoff and Seacat 2001;
Pastoor et al. 1987). PFOS also decreases body
weight (BW), serum cholesterol, and triglyc-
erides and increases liver weight (Butenhoff
and Seacat 2001; Seacat et al. 2002).
Many of the effects observed in animals
after exposure to PFOS suggest the involve-
ment of the central nervous system, specifi-
cally, the neuroendocrine system. However,
no studies to date have assessed the effects of
PFOS on the neuroendocrine system. In the
present study we focused on the effects of
PFOS on two axes of the neuroendocrine sys-
tem: the reproductive axis and the stress axis.
For this purpose, we measured the accumula-
tion of PFOS in several body tissues, includ-
ing brain, and we studied the effects of PFOS
on neurotransmitters and the hormones that
they regulate. We also examined the effects of
PFOS on other parameters such as food intake
and BW.
Materials and Methods
Animals. Adult female Sprague-Dawley rats
were obtained from Harlan Sprague-Dawley,
Inc. (Indianapolis, IN) and were housed indi-
vidually in temperature (23 ± 2°C) and light-
controlled (lights on from 0500 to 1900 hr)
rooms. They were provided food and water
ad libitum. Two weeks after acclimatization,
rats were exposed to potassium salt of PFOS
(> 96% purity; Tokyo Chemical Industries,
Tokyo, Japan). All protocols were approved
by the University Committee for Animal
Care and Use at Michigan State University.
Treatment. Animals were housed individ-
ually. They were injected intraperitoneally
with either 1 or 10 mg/kg BW of PFOS dis-
solved in dimethyl sulfoxide (DMSO) daily
for 14 days (n = 8 for both groups). The con-
trol animals (n = 8) were injected on the same
schedule with the vehicle (DMSO) only.
Food intake and BW of all animals was mea-
sured daily between 0800 and 1000 hr for 14
days. Estrous cyclicity was also monitored
daily using vaginal cytology (MohanKumar
PS et al. 1994). Animals that had repeated
cycles of proestrus, estrus, and diestrus I and
II, in that order, were called “regular cyclers.”
Those that missed a particular stage(s) repeat-
edly were called “irregular cyclers.” Those
that had prolonged periods of diestrus smears
were said to be in “persistent diestrus.”
Brain microdissection. At the end of treat-
ment, the animals were sacriﬁced when they
were in diestrus, by rapid decapitation
between 1000 and 1100 hr. Their brains were
removed quickly and frozen by placing them
on dry ice. Trunk blood was collected and
serum was separated by centrifugation and
stored at –20°C until analyzed for corticos-
terone and leptin by radioimmunoassay
(RIA). Serial sections (300 µm thick) of the
brain were obtained using a cryostat, which
was maintained at –10°C. The sections were
transferred to cover slips, which were placed
on a cold stage set at –10°C. The paraventric-
ular nucleus (PVN) and the medial preoptic
area (MPA) of the hypothalamus were located
with the help of a stereotaxic atlas (Paxinos
and Watson 1987) and were microdissected
using the Palkovits’s micropunch technique
(MohanKumar SMJ et al. 1998; Palkovits
1973). The PVN regulates the stress axis, and
the MPA regulates the reproductive axis. Tissue
samples were obtained bilaterally and included
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Perﬂuorooctane sulfonate (PFOS) is a degradation product of sulfonyl-based ﬂuorochemicals that
are used extensively in industrial and household applications. Humans and wildlife are exposed to
this class of compounds from several sources. Toxicity tests in rodents have raised concerns about
potential developmental, reproductive, and systemic effects of PFOS. However, the effect of PFOS
on the neuroendocrine system has not been investigated thus far. In this study, adult female rats
were injected intraperitoneally with 0, 1, or 10 mg PFOS/kg body weight (BW) for 2 weeks. Food
and water intake, BW, and estrous cycles were monitored daily. At the end of treatment, PFOS
levels in tissues were measured by high-performance liquid chromatography (HPLC) interfaced
with electrospray mass spectrometry. Changes in brain monoamines were measured by HPLC
with electrochemical detection, and serum corticosterone and leptin were monitored using
radioimmunoassay. Treatment with PFOS produced a dose-dependent accumulation of this
chemical in various body tissues, including the brain. PFOS exposure decreased food intake and
BW in a dose-dependent manner. Treatment with PFOS affected estrous cyclicity and increased
serum corticosterone levels while decreasing serum leptin concentrations. PFOS treatment also
increased norepinephrine concentrations in the paraventricular nucleus of the hypothalamus.
These results indicate that exposure to PFOS can affect the neuroendocrine system in rats. Key
words: corticosterone, hypothalamus, leptin, neuroendocrine, norepinephrine, PFOS, reproduc-
tion, stress. Environ Health Perspect 111:1485–1489 (2003). doi:10.1289/ehp.6128 available via
http://dx.doi.org/ [Online 3 April 2003]
Research | Articleall subdivisions of the nuclei. They were stored
at –70°C until analyzed for norepinephrine
(NE) and dopamine (DA) concentrations by
high-performance liquid chromatography
(HPLC) with electrochemical detection.
Neurotransmitter analysis. The concentra-
tions of NE and DA were measured using
HPLC with electrochemical detection, which
has been described before (MohanKumar PS et
al. 1994; MohanKumar SMJ et al. 1998).
Briefly, the apparatus consists of an LC-4C
amperometric detector (Bioanalytical Systems,
West Lafayette, IN); a phase II, 5-µm ODS
reverse-phase C-18 column (Phenomenex,
Torrance, CA); a glassy carbon electrode, a
model CTO-10 AT/VP column oven, and an
LC-10 AT/VP pump (Shimadzu, Columbia,
MD). The mobile phase was made with pyro-
gen-free water and contained monochloroacetic
acid (14.14 g/L), sodium hydroxide (4.675 g/L),
octanesulfonic acid disodium salt (0.3 g/L),
ethylenediaminetetraacetic acid (0.25 g/L),
acetonitrile (3.5%), and tetrahydrofuran
(1.4%). The mobile phase was then filtered
and degassed through the Milli-Q puriﬁcation
system (Millipore Co., Bedford, MA) and
pumped at a flow rate of 1.8 mL/min. The
sensitivity of the detector was 1 nA full scale,
and the potential of the working electrode was
0.65 V. The temperature of the column was
maintained at 37°C. At the time of HPLC
analysis, tissue samples were homogenized in
150 µL 0.1 M HClO4 and centrifuged at
10,000 × g for 10 min; 50 µL of the super-
natant along with 25 µL of the internal stan-
dard (0.05 M dihydroxybenzylamine) was
injected into the HPLC system.
PFOS analysis. Details of the analytical
procedure to measure PFOS have been out-
lined previously (Giesy and Kannan 2001;
Hansen et al. 2001; Kannan et al. 2001a,
2001b, 2002). Briefly, tetrabutylammonium
hydrogen sulfate is added as an ion-pairing
reagent to the homogenized tissues, and the
analyte ion pair is partitioned into methyl-tert-
butyl ether. The extract is dried under a nitro-
gen evaporator, and the solvent is reconstituted
in 1.0 mL of methanol. The analyses were per-
formed with an HPLC interfaced with an elec-
trospray mass spectrometer, by monitoring the
primary ion characteristic of PFOS. Molecular
ion 499 was selected as the primary ion for
PFOS (C8F17SO3).
The following conditions were used for the
analytical phase of this study: For liquid chro-
matograph, we used Hewlett-Packard Series
1100 Liquid Chromatograph System (Hewlett
Packard, Palo Alto, CA) Analytical Column:
Keystone Betasil C18 2 × 50 mm (5 µm;
Thermo Hypersil-Keystone, Bellefonte, PA).
Column temperature was ambient. Of mobile
phase components, component A was 2 mM
ammonium acetate and component B was
methanol; ﬂow rate was 300 µL/min, and injec-
tion volume 10 µL. The mass spectrometer
used was Micromass API/Mass Spectrometer
Quadrupole System; software, Mass Lynx 3.4
(Waters, Milford, MA); cone voltage was
30–60 V; collision gas energy was 25–45 eV;
mode was electrospray negative; and source
block temperature was 150 ± 10°C.
RIA. Double antibody RIA was used to
measure leptin and corticosterone levels in the
serum. RIA kits from Linco Research Inc. (St.
Charles, MO) and the Coat-A-Count kit from
Diagnostic Products Inc. (Los Angeles, CA)
were used to measure leptin and corticosterone
levels, respectively, as described previously
(Francis et al. 2000).
Statistical analysis. Changes in average
daily food intake, BW, and water intake were
analyzed by repeated measures analysis of
variance (ANOVA) followed by Fisher’s least
signiﬁcant difference (LSD). Changes in PFOS
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Figure 1. Structures of PFOS and related compounds. (A) PFOS. (B) Perfluorooctane sulfonylamide. (C)
Perﬂuorooctanoic acid.
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Table 1. PFOS concentrations in serum (ng/mL) and in various tissues (ng/g) on a wet weight basis.
PFOS-treated groups
Site Untreated control 1 mg/kg BW 10 mg/kg BW
Serum BDL 10,480 ± 1,428 45,446 ± 4,120*
Tissue
Liver BDL 26,617 ± 4,044 97,358 ± 25,668*
Heart BDL 1,280 ± 697 23,490 ± 10,036*
Kidneys BDL 9,581 ± 4,836 47,799 ± 29,512*
Spleen BDL 76 15,873
Ovary BDL 3,028 15,489
Adrenal BDL 1,539 30,087
Brain
Hypothalamus BDL < 50 15,706
Cortex BDL 294 4,487
Hippocampus BDL 115 8,966
Brain stem BDL 363 5,346
Cerebellum BDL 289 5,540
Rest of the brain BDL 396 4,256
BDL, below detection limit (50 ng/g). Tissues from animals in each group were pooled for the measurement of PFOS con-
centrations in speciﬁc parts of the brain and in spleen, ovaries, and adrenals. n = 4–5 in each group of rats.
*p < 0.05 relative to the other groups.and neurotransmitter concentrations and in
leptin and corticosterone levels were analyzed
by ANOVA followed by Fisher’s LSD test.
Changes in estrous cyclicity was analyzed by
Kruskal-Wallis nonparametric test.
Results
Accumulation of PFOS in tissues. Con-
centrations of PFOS in various tissues of rats
exposed to either of two doses of PFOS are
shown in Table 1. Although PFOS was not
detectable in any of the tissues in control ani-
mals, there was a dose-dependent increase in
the concentrations of PFOS in all of the
tissues, including various parts of the brain
from exposed rats. PFOS was also found in
the brains of rats exposed to the lower dose.
Among the various parts of the brain, the
hypothalamus of rats exposed to the higher
dose had greater accumulation, with at least a
3-fold increase compared with other brain
areas. However, PFOS was not detected in the
hypothalamus of the rats exposed to the lower
doses. Among various body tissues, the liver
contained the highest concentration, followed
by the kidney and serum.
Body weight. There were no signiﬁcant dif-
ferences in BW among the treatment groups at
the beginning of the experiment. BW (mean ±
SE) in control animals on day 0 (pretreatment)
was 233.5 ± 8.7 g and remained at about that
level on day 14 (240.1 ± 8.2 g). In contrast,
BW in animals treated with the high dose of
PFOS (10 mg/kg of BW) was 235.9 ± 8 g on
day 1 and decreased signiﬁcantly to 208 ± 7.1 g
by day 14 (p = 0.0039; F = 7.306; df = 2).
Treatment with the low dose of PFOS did
not produce any significant change in BW
throughout the treatment period (Figure 2).
Food intake. Changes in food intake
among the treatment groups are shown in
Figure 3. The daily food intake (mean ± SE) of
control animals on day 0 (pretreatment) was
16.3 ± 0.5 g, which did not vary signiﬁcantly
over the study period. In contrast, treatment
with the high dose of PFOS (10 mg/kg of
BW) decreased food intake signiﬁcantly from
16.7 ± 0.7 g on day 1 to 9.1 ± 0.6 g on day 14
(p < 0.0001; F = 60.979, df = 2). Food intake
in animals that were treated with the low dose
of PFOS (1 mg/kg of BW) was similar to that
in controls.
Estrous cycles. Figure 4 shows the changes in
estrous cyclicity among the treatment groups.
All the animals in the control group exhibited
regular 4-day estrous cycles. In contrast, only
about 66% of the animals were regular cyclers in
the low-dose group. Treatment with the high
dose of PFOS further reduced the number of
regular cyclers to 42% and increased the num-
ber of animals in persistent diestrus from 8% in
the low-dose group to 33%. There was a signiﬁ-
cant change in cyclicity between the control and
high-dose group (p= 0.0442; df = 2).
Serum leptin. At the end of treatment, the
leptin level (mean ± SE; Figure 5) in the sera
of control animals was 10.5 ± 1.5 ng/mL.
Treatment with the low dose of PFOS did not
produce any signiﬁcant changes in serum lep-
tin levels. In contrast, treatment with the high
dose of PFOS resulted in a marked decrease in
serum leptin levels (1.5 ± 0.5 ng/mL; p =
0.0183; F = 5.399, df = 2).
Serum corticosterone. The corticosterone
level (mean ± SE; Figure 6) in the sera of
control animals at the time of sacrifice was
332.6 ± 62.8 ng/mL. Treatment with the low
dose of PFOS did not affect serum corticos-
terone levels. In contrast, treatment with the
high dose of PFOS signiﬁcantly increased cor-
ticosterone levels by about 75% (p = 0.0256;
F =4 .814, df = 2).
Monoamines in the hypothalamus. Cate-
cholamine concentrations in the PVN and
the MPA are shown in Figure 7. The NE
level (mean ± SE protein) in the PVN of con-
trol animals was 11.2 ± 1.6 pg/µg. The level
was signiﬁcantly higher (19.7 ± 1.6 pg/µg) in
animals treated with the high dose of PFOS
(p = 0.0413; F = 3.786, df = 2). Treatment
with the low dose of PFOS did not affect NE
concentrations in the PVN. Treatment with
either the low dose or high dose of PFOS did
not affect NE concentrations in the MPA.
PFOS treatment did not affect DA concentra-
tions in either the PVN or the MPA.
Discussion
In this study, PFOS was found in various body
tissues, including the blood, liver, serum, kid-
ney, heart, ovaries, adrenal, brain, and spleen
(Table 1). The liver is the target organ of accu-
mulation for PFOS (Borges et al. 1978;
Butenhoff and Seacat 2001; Pastoor et al.
1987). The concentration of PFOS in the liver
was 2–3-fold greater than that found in serum.
Preferential accumulation of PFOS in the liver
has been suggested because of its binding with
speciﬁc proteins found in the liver (Luebker et
al. 2002; Pastoor et al. 1987). Measured con-
centrations of PFOS in the liver of rats used in
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Figure 2. Changes in BW (mean ± SE) after treatment
with DMSO (control) or with 1 or 10 mg PFOS/kg of
BW/day. BW was measured daily after treatment of
animals. n= 8 in each group. 
*p< 0.05 compared by one-way repeated-measures ANOVA.
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Figure 3. Changes in food intake (mean ± SE) after
treatment with DMSO (control) or with 1 or 10 mg
PFOS/kg of BW/day. Food intake was measured
daily after treatment of animals. n = 8 in each group. 
*p < 0.05 compared by one-way repeated measures
ANOVA.
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Figure 4. Changes in estrous cycles after treatment
with DMSO (control) or with 1 or 10 mg PFOS/kg of
BW/day. Estrous cycles were monitored by daily
vaginal cytology. n = 8 in each group.
Figure 5. Changes in serum leptin levels (mean ± SE)
after treatment with DMSO (control) or with 1 or 10
mg PFOS/kg of BW/day. Serum leptin levels were
measured at the end of 2 weeks of treatment at the
time of sacriﬁce. n = 8 in each group.
*p < 0.05 compared with control and low-dose groups.
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Figure 6. Changes in serum corticosterone (mean ±
SE) levels after treatment with DMSO (control) or
with 1 or 10 mg PFOS/kg of BW/day. Serum corti-
costerone levels were measured at the end of 2
weeks of treatment at the time of sacriﬁce. n = 8 in
each group. 
*p < 0.05 compared with control and low-dose groups.
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Control Low-dose PFOSthis study were higher than the levels reported
in wildlife (48–2630 ng/g; Giesy and Kannan
2001). However, PFOS concentrations mea-
sured in the serum of rats treated with the low
dose of PFOS were similar to the levels
reported in individuals occupationally exposed
to this compound (9,930 and 12,830 ng/mL;
Olsen et al. 1999). In addition, human blood
contains several perfluorinated compounds
such as perfluorooctanoic acid, which are
thought to have effects similar to those of
PFOS (Hansen et al. 2001; Olsen et al. 2000).
Thus, the changes in neuroendocrine func-
tions observed in our study may have implica-
tions for the populations that are affected by
occupational exposure to these compounds.
PFOS exposure in our study produced
marked changes in the BW and food intake of
rats. The decreases in food intake and BW
were followed by a significant reduction in
serum leptin levels by the end of 2 weeks. In
contrast, there was a signiﬁcant increase in cor-
ticosterone and NE concentrations in the PVN
after high-dose PFOS exposures. This indicates
that PFOS has a stimulatory effect on the stress
axis. Apart from affecting the stress axis, PFOS
treatment also altered estrous cyclicity signiﬁ-
cantly. Taken together, these results indicate
that PFOS has marked effects on the neuro-
endocrine system. Our study also indicates that
these effects are probably mediated through an
increase in the accumulation of PFOS in brain
tissues, speciﬁcally, the hypothalamus.
A few studies have investigated the toxic
effects of PFOS in rats, mice, guinea pigs, rab-
bits, and monkeys [reviewed by Starkov and
Wallace (2002)]. Some of the signs of toxicity
observed in these studies included liver abnor-
malities such as hepatomegaly, hepatocyte
swelling and vacuolation, decreased food con-
sumption, and loss of BW. Our results agree
with these findings on food intake and BW.
Exposure to the high dose of PFOS signifi-
cantly decreased food intake and produced a
corresponding decrease in BW. However,
the gross and histologic examinations of the
liver did not show any signs of abnormality.
The discrepancy could be attributed to differ-
ences in doses (20 µg/kg to 30 mg/kg BW),
duration (2–14 weeks), and the routes of
administration (oral or intraperitoneal) among
various studies.
The decrease in BW after treatment with
the high dose of PFOS was accompanied by a
significant decrease in serum leptin levels.
Leptin is a protein hormone produced by
white adipocytes and is involved in the regula-
tion of various neuroendocrine functions,
including food intake (Ahima 2000). Leptin
levels are positively correlated with body fat.
The increase in serum leptin levels is believed
to decrease food intake, and vice versa (Ahima
2000). The low leptin levels observed in
PFOS-exposed rats could be correlated with
the reduced body fat stores observed during
autopsy. However, this reduction in leptin lev-
els failed to stimulate food intake in the treated
animals, suggesting a possible derailment of the
neurotransmitter activity that regulates feeding
behavior. The inhibitory effect of PFOS expo-
sure on food intake was therefore independent
of the effect of PFOS on serum leptin levels.
The low levels of leptin could possibly explain
the reduction in cholesterol and triglycerides
observed with PFOS treatment in other studies
(Kannan et al. 2002; Seacat et al. 2002), and
might be linked to the reduction in 3-hydroxy-
3-methylglutaryl coenzyme A (HMG CoA)
reductase that has been observed (Haughom
and Spydevold 1992).
Our present observations indicate that
PFOS exposure significantly alters estrous
cyclicity in female rats. Adult female rats gener-
ally exhibit 4–5-day estrous cycles. Although all
of the control animals were regular cyclers,
treatment with the low dose of PFOS (1 mg/kg
BW) altered the pattern of estrous cyclicity and
reduced the number of regular cyclers in this
group. Treatment with the high dose of PFOS
(10 mg/kg BW) further affected the estrous
cycles, rendering almost 60% of the treated ani-
mals irregular cyclers. Although PFOS has been
shown to produce an increase in neonatal mor-
tality (Case et al. 2001a, 2001b), its effects on
reproductive cycles have not been reported
before. This study shows for the ﬁrst time that
PFOS can affect estrous cyclicity and can there-
fore function as an endocrine disruptor.
Estrous cyclicity is regulated by the MPA of
the hypothalamus. The MPA houses a large
number of luteinizing hormone (LH)–releasing
hormone (LHRH) neurons (MohanKumar PS
et al. 1994; Ramirez et al. 1984). This hor-
mone is very important for the induction of
the preovulatory LH surge from the pituitary
during the afternoon of proestrus of each
estrous cycle. This surge is responsible for
ovulation and is critical for maintaining
estrous cyclicity in animals. Increase in nora-
drenergic activity in the MPA is very impor-
tant for the stimulation of LHRH neurons,
and thereby the regulation of estrous cycles
(MohanKumar PS et al. 1994; Ramirez et al.
1984). In the present study, although PFOS
treatment disrupted estrous cycles, it did not
result in changes in NE concentrations in the
MPA. This could be attributed to several
causes. First, NE levels in the MPA were mea-
sured after the animals had been sacriﬁced on
the day of diestrus. The day of diestrus is
marked by the absence of ﬂuctuations in NE,
LHRH, and LH. Therefore, it is not surprising
that we did not see any difference in NE on
this day, between control and experimental
animals. Monitoring the changes in neuro-
transmitters and hormones simultaneously at
various time points through the day during
proestrus will help us to determine whether
PFOS-induced alterations in estrous cycles are
accompanied by changes in the levels of LH
and NE. Nevertheless, results from the present
study indicate that PFOS can affect estrous
cyclicity. The mechanism for this alteration
needs further investigation.
Besides affecting the reproductive axis,
PFOS treatment produced marked changes in
the stress axis. PFOS was able to increase serum
corticosterone in treated rats, in a dose-depen-
dent fashion. This effect could again be medi-
ated through the hypothalamus. The PVN of
the hypothalamus has a large number of corti-
cotropin-releasing hormone neuronal cell
bodies and receives rich noradrenergic inner-
vation from the brainstem, through the
ventral noradrenergic bundle (Petrusz and
Merchenthaler 1992). Studies involving neu-
rotoxic blockade of noradrenergic fibers and
direct administration of NE into the PVN
have demonstrated the importance of NE in
the regulation of corticosterone secretion
(e.g., Szafarczyk et al. 1988). In the present
study, PFOS treatment signiﬁcantly increased
NE concentrations in the PVN. This effect
was probably responsible for the increase in
corticosterone observed in the PFOS-treated
rats. The only other study that has examined
the effects of PFOS on the stress axis showed
no changes in cortisol levels, in monkeys, 5–9
weeks after cessation of treatment (Seacat et
al. 2002). However, changes in the levels of
cortisol during the treatment period were not
assessed in that study. In the present study,
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Figure 7. Changes in NE and DA levels (mean ± SE) in (A) MPA and (B) PVN in controls and in experimental
animals treated with PFOS. NE and DA concentrations in speciﬁc areas were measured as described in
“Materials and Methods.” n = 8 in each group.
*p < 0.05 compared with the other groups.
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* A Bwe measured corticosterone levels immedi-
ately after the end of treatment and found
significant alterations, indicating that the
stress axis was activated by PFOS exposure.
The mechanism by which PFOS affects
brain neurotransmitters is not clear. It is possi-
ble that the neurons of the hypothalamus are
exposed to higher levels of PFOS. Table 1
shows the levels of PFOS in various brain
areas. We were able to detect signiﬁcant levels
of PFOS in several parts of the brain, including
the hypothalamus. PFOS concentrations in the
hypothalamus of rats exposed to high doses
were at least 3-fold higher than in other brain
areas. Occurrence of PFOS in the brain sug-
gests that this compound can cross the
blood–brain barrier. The increased levels of
PFOS in the hypothalamus after treatment
with the high dose of PFOS compared with
the low-dose group indicates that the higher
dose may cause an increase in the permeability
of the blood–brain barrier to this compound.
The increase in PFOS levels in the microenvi-
ronment around neurons could possibly con-
tribute to the alterations in their activity. The
exact mechanisms by which PFOS brings about
these changes require further investigation.
Nevertheless, our results provide the ﬁrst evi-
dence that peripheral administration of PFOS
can result in its accumulation in the brain and
this may be a possible route by which PFOS
affects central and neuroendocrine functions.
In summary, exposure to PFOS was found
to activate the stress axis while inhibiting the
reproductive axis. PFOS was also found to
decrease food consumption, BW, and serum
leptin levels. Although the mechanism by
which PFOS produces its neuroendocrine
effects is still unclear, our study indicates that
hypothalamic NE could play a role in this phe-
nomenon. Further studies are needed to charac-
terize the role and mechanism of hypothalamic
NE in precipitating the neuroendocrine effects
of PFOS.
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